Project Details
Description
PROJECT SUMMARY
Duchenne muscular dystrophy (DMD) is the most common type of muscular dystrophy, caused due to mutations
in the dystrophin gene. DMD is characterized by progressive muscle wasting and overall loss of muscle function.
DMD patients become wheel chair dependant by 12 years of age and the associated cardiorespiratory
complications result in their early death around 20 years of age. Dystrophinopathies, which include DMD and
the less severe phenotype Becker, are X-linked recessive disorders affecting primarily males, with 16,765
patients in the US. There is no cure for DMD and corticosteroids such as prednisone are used for symptomatic
relief. Many emerging therapeutic approaches such as exon skipping, gene correction and adeno-associated
virus (AAV) mediated gene therapy aim to increase dystrophin production but are restricted by the immune
response, questionable efficacy, short term effect, high cost and are limited to certain mutations. Cell therapies
have tremendous potential to treat degenerative conditions and genetic diseases. However, to date, production
scalability, safety and efficacy of cell therapy have limited the clinical transition of cell therapies. Myogenica has
developed MyoPAXon, a cGMP certified, induced pluripotent stem cell (iPSC) derived myogenic platform which
regenerates skeletal muscle, leading to functional improvement. MyoPAXon not only replaces diseased muscle
fibers with normal functional muscle fibers but also creates a muscle stem cell pool, enabling long-term muscle
regeneration. Preclinical animal studies of intramuscular, intravascular and intra-arterial transplantation of
MyoPAXon have shown significant engraftment and functional improvement. Myogenica has advanced
intramuscular delivered MyoPAXon toward the clinic, with an IND expected in Q2 this year and first DMD patients
to be treated later this year. As a next step, Myogenica seeks to develop systemically delivered MyoPAXon. The
current STTR Fast track project, aimed at validating the efficacy and safety of systemic MyoPAXon
delivery in preclinical animal models, will be carried out in collaboration with the University of Minnesota.
Systemic MyoPAXon delivery will allow for the targeting of multiple skeletal muscles with a single injection,
making it a compelling therapy for DMD patients and for a range of muscular dystrophies, since MyoPAXon’s
mechanism is not mutation specific. During Phase I-Aim 1, we will select an optimal systemic delivery route (IV
or IA) and conduct dose finding studies in immunodeficient NSG mice, assessing comparative engraftment. This
will be followed by a preliminary safety assessment in Aim 2 where the presence of human cells in non-target
tissues and organs of mice will be evaluated. In Phase II-Aim 1 will continue evaluating efficacy in the immune
deficient, -NSGmdx4Cv mouse model for DMD, using the optimised dose and route determined in Phase I. During
the Phase II-Aim 2, comprehensive GLP toxicology and pharmacokinetics will be performed on NSG mice which
will be followed by safety and biodistribution evaluation in a Non-Human Primate (NHP) model. The results
obtained from this STTR proposal will be leveraged in an Investigational New Drug (IND) application for clinical
studies of systemic MyoPAXon.
Status | Active |
---|---|
Effective start/end date | 9/25/23 → 8/31/24 |
Funding
- National Institute of Arthritis and Musculoskeletal and Skin Diseases: $292,719.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.